Conclusions In the present study, we report
the existence of a new pathway for arresting cell growth that involves the interaction of troglitazone-induced VEGF and NRP-1 in click here NSCLC cells. This suggests that TZDs may be effective anti-cancer agents, and it may be possible to develop a new anti-cancer therapy if the mechanisms underlying these anti-cancer effects are better understood. Acknowledgements This work was LOXO-101 ic50 supported by a Grant-in-Aid for Young Scientists (B) (20790562) to ST from the Ministry of Education, Science, Sports and Culture, Japan. References 1. Spiegelman BM: PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507–514.PubMedCrossRef 2. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proceedings of the National
Academy of Sciences of the United States of America 1998, 95:8806–8811.PubMedCrossRef 3. Lambe KG, Tugwood JD: A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. European Journal of Biochemistry 1996, 239:1–7.PubMedCrossRef 4. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: Terminal differentiation Decitabine purchase of human breast cancer through PPAR gamma. Molecular Cell 1998, 1:465–470.PubMedCrossRef HM781-36B ic50 5. Takahashi N, Okumura T, Motomura L, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. Febs Letters 1999, 455:135–139.PubMedCrossRef 6. Heaney AP, Fernando M, Yong WH, Melmed S: Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting
pituitary adenomas. Nature Medicine 2002, 8:1281–1287.PubMedCrossRef 7. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004, 23:100–108.PubMedCrossRef 8. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Research 1998, 58:3344–3352.PubMed 9. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y: Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells. Cancer Research 2000, 60:5558–5564.PubMed 10.